Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides a source of calories and acts as a substrate for cellular metabolism, replenishing glucose stores. Sodium chloride provides electrolytes for maintenance of osmotic pressure and fluid balance.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Intravenous rehydration and maintenance of fluid and electrolyte balance,Provision of calories in parenteral nutrition,Treatment of dehydration,Vehicle for drug administration
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous; adult dose is 500-1000 m L at a rate of 100-200 m L/hour; frequency depends on fluid and electrolyte needs; maximum rate up to 400 m L/hour in hypovolemic states.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Not applicable as a terminal half-life; dextrose is rapidly cleared from circulation with a metabolic clearance rate of ~15-20 mg/kg/min under normal conditions. The half-life of infused glucose is approximately 15-30 minutes due to rapid cellular uptake and metabolism.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Dextrose is metabolized via glycolysis and the tricarboxylic acid cycle. Sodium chloride is not metabolized but excreted primarily by the kidneys.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Dextrose is metabolized to carbon dioxide and water via glycolysis and the citric acid cycle; essentially eliminated as CO₂ (exhaled) and water (renal, insensible loss). Sodium and chloride are primarily excreted renally (95%) with minor fecal (<2%) and sweat losses.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Negligible (<1%); dextrose does not bind to plasma proteins. Sodium and chloride are not protein bound.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Dextrose distributes into total body water (~0.55 L/kg). Sodium distributes primarily in extracellular fluid (~0.2 L/kg). Volume of distribution for dextrose and electrolytes is not clinically meaningful as a single value.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intravenous: 100%. Oral dextrose: variable but high; not applicable for this formulation, which is IV only. Sodium chloride is completely bioavailable via IV.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
For GFR <30 m L/min/1.73 m²: reduce infusion rate to 50-100 m L/hour; monitor serum sodium and glucose; avoid in anuria.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to risk of fluid overload and hyperglycemia.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Intravenous; weight-based dose: 5-10 m L/kg; infusion rate: 2-6 m L/kg/hour; adjust based on age, weight, and clinical status; maximum 100 m L/kg/day in term neonates.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Elderly: use lowest effective dose; infusion rate: 50-100 m L/hour; monitor for fluid overload, hyperglycemia, and electrolyte imbalance due to decreased renal and cardiac function.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Not applicable; no FDA black box warning for this combination product.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Monitor serum glucose and electrolytes, especially in patients with diabetes mellitus or renal impairment,Avoid use in patients with known hypersensitivity to corn or corn products,Risk of fluid overload in patients with heart failure or renal insufficiency,Use with caution in patients with hyperglycemia, hyponatremia, or hypernatremia,Do not administer simultaneously with blood products
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hyperglycemia,Hypernatremia,Hypersensitivity to dextrose or sodium chloride,Patients with known allergy to corn
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No significant food interactions; however, dietary sodium intake should be considered in patients with hypertension or edema.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Dextrose 5% and sodium chloride 0.225% is considered compatible in pregnancy when used as a vehicle or for correction of fluid and electrolyte disturbances. No teratogenic effects are expected at standard infusion rates. However, excessive administration may cause maternal hyperglycemia, which can lead to fetal hyperinsulinism and neonatal hypoglycemia. No known structural teratogenicity.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Dextrose and sodium chloride are normal constituents of breast milk. Infusion of this solution does not pose a risk to the nursing infant. No M/P ratio data available; both components are naturally present in human milk.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pregnancy induces increased plasma volume and glomerular filtration rate, which may require higher infusion rates to achieve desired correction. However, standard dosing is typically adequate; adjust based on clinical response and serum electrolyte monitoring.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Use cautiously in pediatric and elderly patients to avoid fluid overload and electrolyte imbalance. Monitor serum sodium, glucose, and osmolarity in patients with renal impairment or hyperglycemia. Do not administer if solution is discolored or contains particulates.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Report signs of fluid overload (swelling, rapid weight gain, shortness of breath).,Advise patients with diabetes that this solution contains dextrose and may affect blood glucose levels.,Inform patients that intravenous administration requires careful monitoring by healthcare professionals.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.225% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% is a Electrolyte that works by Dextrose provides a source of calories and acts as a substrate for cellular metabolism, replenishing glucose stores. Sodium chloride provides electrolytes for maintenance of osmotic pressure and fluid balance.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.225% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.225% is: Intravenous; adult dose is 500-1000 m L at a rate of 100-200 m L/hour; frequency depends on fluid and electrolyte needs; maximum rate up to 400 m L/hour in hypovolemic states.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.225% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.225% is classified as Category A/B. Dextrose 5% and sodium chloride 0.225% is considered compatible in pregnancy when used as a vehicle or for correction of fluid and electrolyte disturbances. No teratogenic effects . AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.